Two Stage, Multi-center Trial of Candonilimab in Combination With LM-302 for Treatment of Patients With Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Latest Information Update: 25 Feb 2026
At a glance
- Drugs Cadonilimab (Primary) ; TPX 4589 (Primary)
- Indications Biliary cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Feb 2026 Planned End Date changed from 1 Aug 2026 to 1 Dec 2026.
- 20 Feb 2026 Planned primary completion date changed from 1 Aug 2025 to 1 May 2026.
- 20 Feb 2026 Status changed from recruiting to active, no longer recruiting.